Kadmon Holdings Inc. (NYSE:KDMN) is Attracting Smart Money


In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kadmon Holdings Inc. (NYSE:KDMN) reported that GoldenTree Asset Management has picked up 7,007,712 of common stock as of 2017-08-03.

The acquisition brings the aggregate amount owned by GoldenTree Asset Management to a total of 7,007,712 representing a 12.9% in the company.

For those not familiar with the company, Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases.

A glance at Kadmon Holdings Inc. (NYSE:KDMN)’s key stats reveals a current market capitalization of 114.58M based on 51.85M shares outstanding and a price at last close of $2.21 per share.

Looking at insider activity, there are a few recent transactions worth noting.

Specifically, on 2017-03-13, Loeb picked up 1,488,095 at a purchase price of $3.36 per share.This brings their total holding to 9,407,745 as of the date of the filing.

On the sell side, the most recent transaction saw Goldentree unload 13,839 shares at a sale price of $2.60. This brings their total holding to 228,198.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kadmon Holdings Inc. (NYSE:KDMN) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.